天新药业(603235) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 618,910,665.47, representing a year-on-year increase of 25.16% compared to CNY 494,498,107.04 in the same period last year[4] - Net profit attributable to shareholders was CNY 218,567,101.74, up 48.13% from CNY 147,549,004.33 year-on-year[4] - Basic earnings per share rose to CNY 0.50, a 47.06% increase from CNY 0.34 in the same period last year[4] - The net profit excluding non-recurring gains and losses was CNY 208,976,403.83, marking a 53.30% increase from CNY 136,315,268.67 year-on-year[4] - The total profit for the period was CNY 259,915,720.06, compared to CNY 175,736,320.18 in the previous year, marking an increase of about 48%[20] - Operating profit for the period was CNY 259,904,968.64, up from CNY 176,366,401.91, reflecting a growth of approximately 47%[20] Cash Flow - The net cash flow from operating activities increased by 93.01%, reaching CNY 181,260,939.22, compared to CNY 93,913,720.58 in the previous year[4] - Cash flow from operating activities generated a net amount of CNY 181,260,939.22, compared to CNY 93,913,720.58 in the same quarter last year, indicating a year-over-year increase of 93%[24] - The company reported cash inflow from investment activities of CNY 1,291,300,379.67, a substantial increase from CNY 143,896,761.18 in Q1 2024[26] - Cash outflow from investment activities totaled CNY 1,006,366,733.99, compared to CNY 262,873,722.59 in the same quarter last year[26] - The company’s cash flow from financing activities generated a net amount of CNY 81,271,054.80, slightly down from CNY 90,747,637.45 in Q1 2024[26] Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,814,847,133.34, reflecting a 3.78% increase from CNY 5,603,291,129.63 at the end of the previous year[5] - Total liabilities decreased to CNY 977,910,048.69 as of March 31, 2025, from CNY 987,405,152.49 at the end of 2024, a reduction of 0.5%[17] - Total current assets increased to ¥3,443,854,577.84 in the latest reporting period, compared to ¥3,331,373,369.70 previously, reflecting a growth of 3.4%[30] - The total liabilities decreased to ¥569,026,318.24 from ¥704,835,472.43, a reduction of approximately 19.2%[32] Shareholder Information - The top ten shareholders include Xu Jiangnan, holding 46.51% of shares, and Xu Jing, holding 13.50%[11] - The total equity attributable to shareholders increased to CNY 4,836,937,084.65 as of March 31, 2025, compared to CNY 4,615,885,977.14 at the end of 2024, marking a growth of 4.8%[18] Research and Development - Research and development expenses for Q1 2025 were CNY 20,722,319.47, a decrease of 9.1% from CNY 22,774,738.56 in Q1 2024[19] - Research and development expenses for Q1 2025 were ¥11,304,137.20, up from ¥9,686,583.82 in Q1 2024, indicating a focus on innovation[35] Non-Recurring Gains and Losses - The company reported a total of CNY 9,590,697.91 in non-recurring gains and losses for the period[6] - The company experienced a decrease in credit impairment losses, which improved from CNY -2,357,578.37 in Q1 2024 to CNY -780,792.60 in Q1 2025[20] Cash Position - Cash and cash equivalents as of March 31, 2025, totaled CNY 1,624,850,171.78, an increase of 50.8% from CNY 1,078,329,053.57 on December 31, 2024[14] - The ending balance of cash and cash equivalents reached ¥1,593,614,601.43, up from ¥2,309,350,155.08 at the end of the previous period[39]